Table 3—

Asthma exacerbations during the stable-steroid and steroid-reduction plases in the intent-to-treat population

Stable-steroid phaseSteroid-reduction phase
OmalizumabPlaceboOmalizumabPlacebo
Asthma exacerbations per petient0.28 (0.15–0.41)0.66 (0.49–0.83)0.36 (0.24–0.48)0.75 (0.58–0.92)
Patients with ≥1 asthma exacerbations35 (12.8)83 (30.5)43 (15.7)81 (29.8)
  • Data were analysed by the generalized Cochran-Mantel-Haenszel test (van Elteren test), and presented as mean (95%, confidence interval) or n (%). p<0.001